Big Benny
2 days ago
Hi J-V,
I read your post with much interest. I owned about the same number of shares in a company called Virtual Sellers Dot Com. That one ended up being a six-figure blowup. Might this be the same? I would be very interested in talking to your broker sometime.
I had three situations like that happen to me. The problem was, I started trading in the old days when the adage "buy and hold" was well-placed advice. Also, my inclination to avoid short term capital gains because of tax implications prevented me from selling. I ended up failing to take my gains on the last two due to that issue. On the first one, I took my gains because most of it was in my traditional IRA. Then the housing bubble hit, and everything went to hell. If that "explosion" could happen again, it would be great vindication for me.
Thanks for your comments. Please keep them coming.
BB
JOHNNY-VEGAS
3 days ago
The same here. Called my broker he assured me everything will be settled next week. I like everything Keener doing recently.Complete Product Overhaul with New Line of Scientifically Advanced Solutions , insider buying, experienced Board Of Directors”Strategic thinking Focusing on big-picture issues and long-term goals Strong understanding of the business comprehensive knowledge of the company's industry, market dynamics, financial health, and key strategic initiatives.” I am just gonna wait patiently to see some progress on the sale side with the new product. The global weight management market was valued at $142.58 billion in 2022. growth expected for The weight loss products market is to grow to $407.9 billion by 2030. If they manage to get a tiny percentage of the market shares,we’re gonna be a very happy campers.
?
Big Benny
3 days ago
Is the dividend in the works? I went on to my brokerage account and the value of my stock is down dramatically. I am guessing that that is in preparation for receiving the stock dividend. Is that what others of you on this board would think as well? This may be a real cash cow by the time all is said and done. After all, even after the stock dividend, there will only be a little over 8 million shares, which is staggering. if they can make 1 million dollars profit after expenses, that would put the share price, (assuming a 10 PE) at around $1.2 per share, a sizeable increase.
BB
Ribo
4 days ago
$BDPT, Director Added
https://www.bioadaptives.com/leadership
Mark P. Frissora
Director
Mark P. Frissora, most recently the CEO and President of Caesars Entertainment, has 42 years of business experience across managerial and functional roles. He joined Caesars in 2015 and previously served as Chairman and CEO of Hertz Global Holdings and Tenneco, Inc., leading both Fortune 500 companies through transformative growth. Frissora has a 20-year track record of creating stakeholder value at highly leveraged companies in private equity and public markets, meeting or exceeding expectations in over 92% of 65 quarters during two significant recessions. He led two companies through successful IPOs and guided Caesars out of bankruptcy to its NASDAQ relisting in 2017. At Tenneco, where he served as Chairman and CEO from 1999 to 2006, shareholder value tripled, revenue rose 39%, and the company earned top industry awards for shareholder returns. During his tenure at Hertz from 2006 to 2014, shareholders saw a 3.6x return post-IPO, with a special dividend paid after the launch. At Caesars, he drove initiatives that increased EBITDA by $812M (55%) and margins by 930 bps, creating $12.5B in value during its bankruptcy turnaround. Frissora currently chairs Arencibia, an advanced engineering company, and co-founded Goodwrx, a gig economy technology solution. He previously served on the boards of Caesars Entertainment, Aptiv, Walgreens Boots Alliance, FMC Corporation, and NCR Corporation, holding key leadership roles on governance, compensation, and finance committees. Mark holds a B.A. from The Ohio State University and has completed executive programs at Babson College and Thunderbird School of Global Management.
tapioca
7 days ago
Ha, yes, no one was buying in the trips, and the volume is 3 today, 🤣. So of course no one is buying here either. Could be that the price has been holding because of the share double plan, which would slow people down from unloading. Just dangling that carrot in front of shareholders. Definitely having some big doubts here now
JOHNNY-VEGAS
2 months ago
Thanks James Keener.
$BDPT BioAdaptives, Inc.’s Board of Directors Approves a One-for-One Stock Dividend
GlobeNewswire6 hours ago
LAS VEGAS, Dec. 03, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (BDPTD.NaE) Board of Directors has approved a dividend to all common stockholders. They will receive matching shares for all of the shares they own on the Record Date.
CEO James Keener stated, “This dividend is designed to acknowledge your steadfast belief in our vision and to reward you for standing by us as valued stakeholders.”
Key Details:
Dividend Structure: One additional share of common stock for each share owned as of the record date.
Record Date: Projected for the second week of January 2025
Payment Date: Within 15 days from the Record Date
Keener added, “This special dividend aligns with our dedication to enhancing shareholder value while reinforcing our focus on long-term growth and success. The additional shares you will receive signify our shared optimism for the future and our determination to deliver
MC10459
2 months ago
The share price doesn't automatically drop when OS is increased. Dilution typically occurs when a company get a "toxic loan" with no intent of paying it back with cash. Instead, they're given the option to pay it back with discounted shares, which they do.
For example: the share price is at .05. The lender is given shares at .005 per share. Let's say the loan $100k. 20 million shares are paid to the lender and added to the outstanding share count. The lender has no intention of hanging onto the shares. They never do. So, they begin to dump. And they will dump at .05, .04, .03, 02. . . and less, thus making a killing. This drives down the share price. That's the effect of dilution.
Adding 4 million shares could drive down the price, if people choose to take profits---if they were green before or if this dividend makes them green. Myself, I'll hang onto to them and stay along for the ride. It could be very interesting.
Right now, this news has driven the pps up.
LJ-Bodhi
2 months ago
Let's unpack this dividend news. Every common shareholder will receive one additional share of stock for every share they own. Wow, great.....yes??? Well, let's just say the same thing in a different way. The company will automatically double the Outstanding Shares on a single day from 4 million to 8 million shares. Ummmm, that doesn't sound so good....no???
All things being equal, the market cap would remain the same, the OS will double, and the share price should plummet to half the price before the stock dividend to maintain equilibrium. As a singular event, the most likely thing this stock dividend will do is drop the price 50%. Sure, an investor will have double the shares, so gains from there will be nice. The question is how low the price will go once the downward pressure subsides from the dumping that will occur on the way down. Smart money will take the free shares and sell them as the price drops to get that free money. Then buy back up on the correction. This stock is going to be interesting. Now, if they could only sell products.....
Remember, no one will know how many shares the lender will convert until the April annual report, so there may be a very rude dilution awakening come next spring. Interesting stock indeed!
Giovanni
2 months ago
Thank you
BioAdaptives, Inc. Announces Institutional Review Board Approval of a Human Clinical Trial for Zeranovia™
LAS VEGAS, Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN –BioAdaptives Inc. (OTC: BDPT) received approval today for a human clinical trial of its weight management product, Zeranovia™.
The trial, approved by an Institutional Review Board, will be managed and supervised by doctors in Las Vegas, Nevada. Sign-ups to participate in the clinical trial have been available on Zeranovia’s website. An excellent response from interested participants quickly filled available positions for the first trial stage. The first phase is designed to confirm dosing and determine if any new side effects are revealed. The next stage of the trial will be open to additional participants.
BioAdaptives™ CEO James Keener stated: “According to data from the National Institutes of Health's Office of Dietary Supplements (ODS), less than 1.0% of nutraceuticals sold in the United States undergo examination in human clinical trials.”
Keener continued: “We are committed to supplying the highest quality products with provable scientific results. Zeranovia’s™ success is based on a high-protein blend of vitamins, minerals, and five concentrated herbal supplements, four of which are adaptogens.”
Before moving Zeranovia™ to BioAdaptives™, Keener’s team spent almost one year in product development, including extensive lab work. Based on those efforts and the knowledge obtained, human clinical trials are expected to mirror the results already achieved. If so, this will be the first natural product that compares favorably to the synthetic medical treatments of GLP-1 and GIP.